Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare CVE:NDVA NASDAQ:VIR NYSEAMERICAN:ZOM On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeNDVAIndivaC$0.03-14.3%C$0.03C$0.02▼C$0.13C$5.87M1.12119,038 shs558,384 shsVIRVir Biotechnology$8.79-3.3%$9.59$4.16▼$11.66$1.53B1.71.63 million shs1.71 million shsZOMZomedica$0.00$0.09▼$0.16$95.35M1.034.72 million shs790,936 shsA Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for May 2026. Learn which stocks have the most short interest and how to trade them. Click the link to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceNDVAIndiva0.00%0.00%0.00%0.00%0.00%VIRVir Biotechnology-3.30%-3.62%-15.97%+17.67%+95.33%ZOMZomedica0.00%0.00%0.00%0.00%0.00%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeNDVAIndivaC$0.03-14.3%C$0.03C$0.02▼C$0.13C$5.87M1.12119,038 shs558,384 shsVIRVir Biotechnology$8.79-3.3%$9.59$4.16▼$11.66$1.53B1.71.63 million shs1.71 million shsZOMZomedica$0.00$0.09▼$0.16$95.35M1.034.72 million shs790,936 shsA Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for May 2026. Learn which stocks have the most short interest and how to trade them. Click the link to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceNDVAIndiva0.00%0.00%0.00%0.00%0.00%VIRVir Biotechnology-3.30%-3.62%-15.97%+17.67%+95.33%ZOMZomedica0.00%0.00%0.00%0.00%0.00%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceNDVAIndiva 0.00N/AN/AN/AVIRVir Biotechnology 2.89Moderate Buy$20.25130.38% UpsideZOMZomedica 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest VIR, ZOM, and NDVA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/8/2026VIRVir Biotechnology Morgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$23.004/10/2026VIRVir Biotechnology Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)3/4/2026VIRVir Biotechnology HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$15.00 ➝ $20.002/26/2026VIRVir Biotechnology Leerink PartnersSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform$20.002/24/2026VIRVir Biotechnology BarclaysSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$26.00 ➝ $30.002/24/2026VIRVir Biotechnology EvercoreSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform$18.002/24/2026VIRVir Biotechnology Morgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$20.00 ➝ $24.002/24/2026VIRVir Biotechnology Raymond James FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeOutperform ➝ Strong-Buy$19.002/24/2026VIRVir Biotechnology Needham & Company LLCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$14.00 ➝ $18.002/17/2026VIRVir Biotechnology BarclaysSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$26.00(Data available from 5/16/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookNDVAIndivaC$37.57M0.16C$0.01 per share5.20N/A∞VIRVir Biotechnology$68.56M21.62N/AN/A$4.82 per share1.82ZOMZomedica$25.19M0.00N/AN/A$0.24 per share0.00Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateNDVAIndiva-C$4.92M-C$0.03N/AN/AN/A-13.09%-544.76%-3.51%N/AVIRVir Biotechnology-$437.99M-$3.13N/AN/AN/A-638.88%-53.31%-41.76%N/AZOMZomedica-$34.53M-$0.06N/AN/AN/A-232.88%-12.47%-11.84%N/ALatest VIR, ZOM, and NDVA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/6/2026Q1 2026VIRVir Biotechnology-$0.01-$0.85-$0.84-$0.85$55.49 million($0.03) million2/23/2026Q4 2025VIRVir Biotechnology-$0.42-$0.31+$0.11-$0.31$19.91 million$64.07 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthNDVAIndivaN/A4.04%N/AN/AN/AVIRVir BiotechnologyN/AN/AN/AN/AN/AZOMZomedicaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioNDVAIndiva5,899.220.720.52VIRVir BiotechnologyN/A7.117.11ZOMZomedicaN/A10.8210.15Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipNDVAIndiva0.06%VIRVir Biotechnology65.32%ZOMZomedica8.95%Insider OwnershipCompanyInsider OwnershipNDVAIndiva36.29%VIRVir Biotechnology16.00%ZOMZomedica4.19%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableNDVAIndiva147,000195.49 millionN/ANot OptionableVIRVir Biotechnology580168.65 million141.67 millionOptionableZOMZomedica50979.95 million938.89 millionNot OptionableVIR, ZOM, and NDVA HeadlinesRecent News About These CompaniesZomedica Corp.: Zomedica Announces "Fifth Friday at Four" Webinar on May 29th: First Quarter 2026 Financial Results and a Deep Dive into the Companion Animal VetTech MarketMay 15 at 10:02 PM | finanznachrichten.deZomedica Corp.: Zomedica Announces Record First Quarter Revenue of $8.8 Million, Reflecting 35% Annual Growth; and $47.5 Million in LiquidityMay 6, 2026 | finanznachrichten.deZomedica Corp. (ZOMDF) Discusses Manufacturing Strategy and Quality Operations for Veterinary Diagnostics and Therapeutics TranscriptApril 24, 2026 | seekingalpha.comZomedica Insider Trading Activity | OTC:ZOMDF | BenzingaApril 7, 2026 | benzinga.comZomedica Corp. (ZOMDF) Discusses the Equine Veterinary Market Opportunity TranscriptMarch 28, 2026 | seekingalpha.comZomedica Corp.: Zomedica Announces Strategic Collaboration with Boehringer Ingelheim to Expand Equine Endocrine Diagnostic Testing Using TRUFORMA PlatformMarch 19, 2026 | finanznachrichten.deZomedica Announces Record Fourth Quarter Revenue of $10.5 Million and Full Year Revenue of $32.0 Million for 2025, Reflecting 17% Annual Growth; Achieves 68% Gross Margin and ...March 16, 2026 | pharmiweb.comPZomedica Corp.: Zomedica to Review 2025 Financial Results and Highlight Equine Market Opportunity During March 27th "Fourth Friday at Four" Investor WebinarMarch 10, 2026 | finanznachrichten.deZomedica Corp. (ZOMDF) Discusses R&D Strategy and Innovation in Veterinary Diagnostic and Therapeutic Technologies TranscriptFebruary 27, 2026 | seekingalpha.comZomedica Corp.: Zomedica Expands Distribution of TRUVIEW Digital Microscopy Platform Through National Agreement with Moichor, a Leader in Veterinary PathologyFebruary 25, 2026 | finanznachrichten.deZomedica Corp.: Zomedica Announces "Fourth Friday at Four" Webinar on February 27th Focused on Research & Development and Its Innovation PipelineFebruary 5, 2026 | finanznachrichten.deZomedica Corp. (ZOMDF) Discusses Technology and Digital Innovation Driving Growth in Animal Health TranscriptJanuary 23, 2026 | seekingalpha.comZomedica Corp.: Zomedica Expands its TRUVIEW Microscopy Platform with AI Diagnostic Interpretation, Growing its Market OpportunityJanuary 23, 2026 | finanznachrichten.deZomedica Corp.: Zomedica Announces "Fourth Friday at Four" Webinar on January 23rd Focused on Digital Innovation & Technology-Driven GrowthJanuary 14, 2026 | finanznachrichten.deModern therapies for patients with chronic painDecember 16, 2025 | dvm360.comDZomedica Corp. (ZOMDF) Q3 2025 Earnings Call TranscriptNovember 21, 2025 | seekingalpha.comFull-body therapy bed is launched for pain management and mobility supportOctober 24, 2025 | dvm360.comDZomedica Corp.: Zomedica Announces Launch of the Assisi Loop Lounge, Scientifically Backed tPEMF Therapy for PetsOctober 23, 2025 | finanznachrichten.deZomedica Corp.: Zomedica Expands TRUFORMA Diagnostic Platform with Addition of Feline Use to Cobalamin & Folate AssaySeptember 23, 2025 | finanznachrichten.deZomedica Corp.: Zomedica's Fourth Friday at Four Webinar Returns: Spotlight on TRUVIEW Digital Cytology Microscope - Transforming Veterinary ImagingSeptember 12, 2025 | finanznachrichten.deNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesThe Real SpaceX Play: 5 Chip Stocks Powering the IPO Before It LaunchesBy Bridget Bennett | May 4, 2026Pipelines and Automation: 2 Energy Plays Built for Any Oil PriceBy Chris Markoch | April 26, 2026TPG Built a Record Year, Then Lost 40%—Is the Selloff Overdone? By Peter Frank | April 16, 2026Alcoa Dips After Q1 Miss, But Higher Aluminum Prices LoomBy Thomas Hughes | April 18, 2026The Volatility Harvester That Thrives in Market ChaosBy Peter Frank | April 27, 2026VIR, ZOM, and NDVA Company DescriptionsIndiva CVE:NDVAC$0.03 -0.01 (-14.29%) As of 06/12/2024Indiva Limited engages in the production, processing, and sale of cannabis and cannabis related products in Canada. It offers pre-rolls, flower, capsules, and edible and extract products under the INDIVA, Indiva Life, and Artisan Batch brands. The company produces and distributes the Bhang Chocolate, Wana Sour Gummies, Jewels Chewable Tarts, Grön edibles, and Dime Industries vape products through license agreements and partnerships. Indiva Limited is based in Ottawa, Canada.Vir Biotechnology NASDAQ:VIR$8.79 -0.30 (-3.30%) Closing price 05/15/2026 04:00 PM EasternExtended Trading$8.65 -0.14 (-1.64%) As of 05/15/2026 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Vir Biotechnology, Inc., an immunology company, develops therapeutic products to treat and prevent serious infectious diseases. Its clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). The company's preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV). The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of Health; an option and license agreement with Brii Biosciences Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with MedImmune, LLC; collaboration with WuXi Biologics (Hong Kong) Limited and Glaxo Wellcome UK Ltd.; and a collaborative research agreement with GlaxoSmithKline Biologicals S.A, as well as license agreement with Sanofi for three clinical-stage masked T-cell engagers (TCEs) and exclusive use of the protease-cleavable masking platform for oncology and infectious diseases. It also has a manufacturing agreement with Samsung Biologics Co.,Ltd. The company was incorporated in 2016 and is headquartered in San Francisco, California.Zomedica NYSEAMERICAN:ZOMZomedica Corp., a veterinary health company, focuses on the unmet needs of clinical veterinarians by developing products for companion animals. The company offers diagnostic products comprising TRUFORMA Bulk Acoustic Wave point of care diagnostic platform; TRUVIEW, a digital cystoscopy platform that offers automated slide preparation within the instrument; and VetGuardian, a zero-touch vital signs remote monitoring system. It also provides therapeutic products, including PulseVet electrohydraulic shockwave therapy platform; and Assisi Loop line of products, including the Assisi Loop, Assisi Loop Lounge, and DentaLoop devices that treat pain and inflammation through delivery of targeted pulsed electromagnetic field focused energy. The company has collaboration agreements with Celsee, Inc. for the development and commercialization of liquid biopsy assays and related consumables for the detection of cancer in companion animals; and Seraph Biosciences, Inc. for the development of a novel pathogen detection system. The company was formerly known as Zomedica Pharmaceuticals Corp. and changed its name to Zomedica Corp. in October 2020. Zomedica Corp. is headquartered in Ann Arbor, Michigan. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 05/11 - 05/15 Datavalut Gains Traction: 5 Reasons to Sell Now TMC Stock: Why This Pre-Revenue Miner Is Worth Watching Viking Sails to All-Time Highs—Fundamentals Signal More to Come YETI Rallies After Earnings Beat and Raised Outlook Aeluma's Post-Earnings Dip Creates a Buying Opportunity Cisco’s Vertical Rally May Still Be in the Early Innings Be Ready: 3 Upcoming Catalysts Could Drive Oracle to Record Highs Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
